that tumor exosomes play in cancer development, metastasis and drug resistance. Tumor cells have been shown to selectively package certain proteins and RNA material into exosomes for the purpose of cell to cell communication. After internalization, recipient cells show altered gene expression, which in turn, modifies their invasiveness, apoptotic rate and sensitivity to therapeutic drugs. Few studies have examined the role of exosomal microRNAs (miRNA) in transference of drug resistance in bladder cancer. We hypothesize, that specific miRNAs have distinct roles in the establishment of chemoresistance. Here we strive to identify exosomal miRNAs profiles and their roles in Cisplatin, Gemcitabine and Cisplatin/Gemcitabine chemoresistance in bladder cancer.
INTRODUCTION AND OBJECTIVES: Bladder cancer is the most common malignancy of urogenital system and one of the major causes of death in Chinese cancer patients. Small RNAs (sRNA) are potential therapeutic drugs for bladder cancers. However, it is still difficult to transport sRNAs stably in the body. Cell-derived exosomes have been demonstrated to be efficient carriers of small RNAs to neighbouring or distant cells, highlighting the preponderance of exosomes as carriers for gene therapy over other artificial delivery tools.
METHODS: In the present study, we employed modified exosomes expressing the iRGD peptide (a tumor-penetrating peptide) on the membrane surface to deliver Survivin siRNA into bladder cancer in a mouse xenograft tumor model. qPCR and western blotting were used to determine the expression of siRNA and survivin in tumor tissues.
RESULTS: We found that Survivin siRNA could be efficiently packaged into iRGD modified exosomes and was associated with argonaute 2 (AGO2) in exosomes. These exosomes efficiently and specifically delivered Survivin siRNA into 5637 bladder cancer cells and the mouse xenograft tumor. Functionally, Survivin siRNA-loaded iRGD exosomes significantly reduced Survivin mRNA and protein levels in bladder cancer cells. Sebsequently, Survivin siRNA delivered by the iRGD modified exosomes strongly inhibited the growth of the mouse xenograft tumor.
CONCLUSIONS: In conclusion, our results demonstrate that targeted iRGD exosomes can efficiently transfer siRNA to bladder cancer and mediate the growth inhibiton of bladder cancer by downregulating Survivin expression levels. Our study provides a brand new strategy to treat bladder cancer.
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MP88-17 PATIENT DERIVED XENOGRAFTS OF UPPER TRACT UROTHELIAL CARCINOMA: A POTENTIAL TOOL FOR PERSONALIZED MEDICINE INTRODUCTION AND OBJECTIVES: Upper tract urothelial carcinomas (UTUC) are treated similarly to urothelial carcinoma of the bladder (UCB). UTUC demonstrates a more aggressive clinical course which may be explained by significant differences in mutational frequencies between UTUC and UCB that were reported using a customized exon capture sequencing assay (the MSK-IMPACTTM e1180 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
